A grant number provides unique identification for the grant. This page provides a comprehensive explanation of all the components of a complete NIH grant number.

The aim of this notice is to provide the biomedical research community with information on the actions that NIH is taking and requiring in response to the guidance given by the White House Office of Science and Technology Policy in accordance with the May 5, 2025 Executive Order on Improving the Safety and Security of Biological Research.

The purpose of this notice is to correct Section III - Eligibility Information for the Ruth L. Kirschstein Research Service Award (NRSA) Fellowships PA-25-422, PA-25-423, PA-25-424, PA-25-425, PA-25-426. 

Section III, Eligibility Information. Eligible Individuals (Program Director/Principal Investigator):

By the time of award, the individual must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status).

Effective 6/12/25, NIH rescinded the Guide Notice 'Notice of Civil Rights Term and Condition of Award' (NOT-OD-25-090). NIH is anticipating additional Federal-wide guidance and will inform the extramural community in the future. The previous guidance is no longer valid.

By way of this Notice, The National Institutes of Health (NIH) announces an automatic extension until October/November 2025 receipt dates for prospective applicants to the NIH Pathway to Independence Award (K99/R00) program. The extension is limited to individuals whose eligibility period under the Parent K99/R00 would have ended between October 2024 – January 2026.

The extramural community is being informed by this notice that NIH has temporarily disabled the No-Cost Extension functionality in eRA Commons. At this time, all requests for NCEs must be submitted as a prior approval request in eRA Commons, for review and approval by the NIH. Requests for activities that do not align with the mission and priorities of the NIH will not be approved.

An automatic extension of Early-Stage Investigator (ESI) eligibility is granted by the National Institutes of Health (NIH) through this Notice. This extension aims to address any delays in grant application submissions, peer review, or award processing timelines between January 1, 2025, and May 31, 2025, and seeks to mitigate their impact on the biomedical research community.

The purpose of this notice is to rescind NOT-DA-21-046 titled “Notice of Information: NIDA Extensions for NRSA Fellowships and Career Development Award Recipients Whose Career Trajectories Have Been Significantly Affected by COVID-19,” effective 06/04/25. NIDA will no longer accept extension or supplement applications due to delays related to COVID-19.

The purpose of this Notice is to inform potential applicants that effective 06/05/25, the Office of Research on Women's Health (ORWH) will participate in PA-25-080 “NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)” issued by the National Institutes of Health.

This Notice is intended to inform the extramural research community of a temporary exception to Section 12.3.7 of the NIH Grants Policy Statement (NIHGPS), which generally limits eligibility for mentored career development (K) awards to those who have not previously been the recipient of such awards.  

Effective 05/28/25, NIH will allow individuals whose mentored career development awards prematurely ended on or after January 1, 2025. To be eligible to apply for a new mentored career development award, it is contingent upon meeting all other eligibility requirements.

This is to notify the research community of the approaching FY25 pre-application deadlines for the Department of Defense (DOD) Melanoma Research Program (MRP) managed by the Congressionally Directed Medical Research Programs (CDMRP).

Pre-proposals due June 30^th; Requires Invitation to Submit Full Application:

·       Idea Award ($560,000 total costs)

·       Team Science Award ($2,100,000 total costs)

·       Focused Program Award – Rare Melanomas ($2,800,000 total costs)

Letter of Intent (LOI) due September 10^th; NO Invitation to Submit Full Application:

·       Melanoma Academy Scholar Award ($770,000 total costs)

·       Melanoma Academy Leadership Award ($1,820,000 total costs)

·       Survivorship Research Award ($1,015,000 total costs)

**Be sure to view the newly posted FY25 MRP Funding Overview webinar and FY25 MRP Funding Opportunity FAQ now available on the MRP webpage, https://cdmrp.health.mil/mrp/default.**

Reminders:

·       All FY25 MRP cost caps are now TOTAL COST caps (direct + indirect costs).

·       All FY25 MRP awards recommended for funding will be fully funded, up front with FY25 funds and have periods of performance that begin no later than 30 September 2026. The availability of future fiscal year appropriations will not impact funding levels of FY25 awards.

Click here to view the funding opportunities for the FY25 Melanoma Research Program (MRP).

To view the program announcements and submit a pre-application visit: 

 https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103

This is to notify the research community of recently released Fiscal Year 2025 (FY25) funding announcements for Department of Defense (DOD) programs managed by the Congressionally Directed Medical Research Programs (CDMRP).

Funding announcements released:

The Toxic Exposures Research Program (TERP) released program announcements for the following funding opportunities:

·       Investigator-Initiated Research Award

·       Translational Research Partnership Award

·       Clinical Trial Partnership Award

To view the program announcements and submit a pre-application visit: 

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=677101

This is to notify the research community of the following modifications to cost caps of FY25 funding opportunities for Department of Defense (DOD) programs managed by the Congressionally Directed Medical Research Programs (CDMRP):

New! Cost caps for all FY25 ALSRP, BCRP, DMDRP, MRP, PRMRP, and PCRP funding opportunities have been changed from direct costs to total costs (direct plus indirect costs).

1.Amyotrophic Lateral Sclerosis Research Program (ALSRP):

The maximum allowable funding for FY25 ALSRP funding opportunities is summarized below:

·       Clinical Outcomes and Biomarkers Award: $1.00M total costs (direct plus indirect costs) 

·       Pilot Clinical Trial Award: $2.80M total costs (direct plus indirect costs)

·       Therapeutic Development Award: $2.00M total costs (direct plus indirect costs)

·       Therapeutic Idea Award: $840,000 total costs (direct plus indirect costs).

To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663102

2.Breast Cancer Research Program (BCRP):

The maximum allowable funding for FY25 BCRP funding opportunities is summarized below:

·       Breakthrough Award Levels 1 and 2 (BTA12):

o  Funding Level 1: $750,000 (single PI) and $1.25M (Partnering PI Option) for total costs (direct plus indirect costs)

o  Funding Level 2: $1.65M (single PI) and $2.5M (Partnering PI Option) for total costs (direct plus indirect costs)

o  Funding Level 2 – Population Science and Prevention Studies: $2.5M (single PI) and $3.35M (Partnering PI Option) for total costs (direct plus indirect costs)

·       Breakthrough Award Level 3: $5.6M (single PI) and $7M (Partnering PI Option) for total costs (direct plus indirect costs)

·       Clinical Research Extension Award: $7M (single PI) and $8.4M (Partnering PI Option) for total costs (direct plus indirect costs)

·       Era of Hope Scholar Award: $4.9M for total costs (direct plus indirect costs).

To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663101

3.Duchenne Muscular Dystrophy Research Program (DMDRP):

The maximum allowable funding for FY25 DMDRP funding opportunities is summarized below:

·       Clinical/Translational Research Award:

o  Funding Level 1: $910,000 (single PI) and $1.00M (Partnering PI Option) for total costs (direct plus indirect costs)

o  Funding Level 2: $1.75M (single PI) and $1.9M (Partnering PI Option) for total costs (direct plus indirect costs)

·       Idea Development Award: $500,000 total costs (direct plus indirect costs)

To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=667101

4.Melanoma Research Program (MRP):

The maximum allowable funding for FY25 MRP funding opportunities is summarized below:

·       Focused Program Award – Rare Melanomas: $2.8M total costs (direct plus indirect costs)

·       Idea Award: $560,000 total costs (direct plus indirect costs) 

·       Melanoma Academy Leadership Award: $1.82M total costs (direct plus indirect costs) 

·       Melanoma Academy Scholar Award: $770,000 total costs (direct plus indirect costs) 

·       Survivorship Research Award: $1.015M total costs (direct plus indirect costs) 

·       Team Science Award: $2.1M total costs (direct plus indirect costs) 

To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103

5.Peer Reviewed Medical Research Program (PRMRP):



The maximum allowable funding for FY25 PRMRP funding opportunity is summarized below:

·       Technology/Therapeutic Development Award: $3.5M total costs (direct plus indirect costs)

To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671101

6.Prostate Cancer Research Program (PCRP):

The maximum allowable funding for FY25 PCRP funding opportunities is summarized below:

·       Clinical Consortium Award:

o  Coordinating Center: $10.5M for total costs (direct plus indirect costs)

o  Clinical Research Sites: $2.0M for total costs (direct plus indirect costs)

·       Idea Development Award:

o  Established Investigators: $1.7M for total costs (direct plus indirect costs)

o  New Investigators: $2.1M for total costs (direct plus indirect costs)

To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=665102

NBME is excited to share that applications are open for two grant programs for medical educators and researchers looking to advance innovations in assessment. We greatly appreciate your interest in our grant programs and would like to ask for your support in sharing this opportunity with your networks.

2026 Stemmler Grants

Apply by June 30, 2025

Targeting mid- and senior-career researchers, this grant supports innovative assessment techniques in medical education or practice. Up to $150,000 will be awarded for each research team. Learn more on NBME’s Stemmler Grant page.

The 2025 Peg’s Fight for Life Award offers $150,000 paid over two years to support early-career researchers focused oncogene-driven lung cancer and related translational research topics. Funding supports salaries and research costs to help retain top scientific talent in the lung cancer field.

Preferred Research Topics

• Overcoming resistance to immunotherapy in EGFR-mutated lung cancer
• Identifying predictive/prognostic markers
• Novel treatment strategies for mutation-driven NSCLC
• Understanding mechanisms of resistance to targeted therapies

Eligibility Criteria

• Early career investigator (within first 10 years of faculty appointment)
• U.S. institution affiliation required
• Mentor support and institutional letter of support required
• Doctoral degree: MD, PhD, DO, DrPH (or equivalent)

Key Dates

• Letter of Inquiry Deadline: June 30, 2025
• Invited Full Proposals Due: August 25, 2025
• Award Announcement: November 2025
• Total Award: $150,000 (paid in $37,500 increments over 2 years)
• Indirect Costs Allowed: Up to 15% included in total award

More Information & Submission Questions?

Contact: Teri Cannon, Executive Director
| 952-405-9201 |research@abreathofhope.org

Read Full RFP

Due: July 1, 2025, 4pm

Amount: $400,000/2 years

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.

Eligibility: The applicant must have received an MD, DO, PhD, or MD/PhD degree. Tenure-track Assistant Professors within the first five (5) years of obtaining their initial Assistant Professor position (Cut-off date: July 1, 2020). Clinical Instructors

and Senior Clinical Fellows (in the final year of sub-specialty training) holding an MD, MD/PhD, DO who are pursuing a period of independent research before taking a tenure-track faculty position. Such individuals must have an exceptional record of research accomplishment, dedicated laboratory space and the support of their institution. Applicants with a background in multiple disciplines are especially encouraged to apply.

Link: Damon Runyon-Rachleff Innovation Award

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

This program has been established to promote, nurture and amplify scientific discovery and innovation in Western New York and the region. The WNYBC Discovery and Innovation Award will support basic, translational, and/or clinical research projects that will improve health outcomes, health equity, and/or preventing complications of hemophilia and/or hemostatic or thrombotic disorders.

We invite proposals from higher education institutions and non-profit organizations that have a history and track record of serving the community of bleeding and clotting disorders. There is no age requirement, however, applicant must have an MD, PhD or equivalent; clearly state they have both independent research projects and independent resources; and have preliminary results/and or publications from their independent laboratory.

Budget must not exceed $150,000/year, for up to three years. Up to two grants will be awarded annually.

APPLICATION DUE DATE July 1, 2025

GRANT START DATE  January 1, 2026

Attached please find the 2025 Grant RFP. 

QUESTIONS? Check the attached FAQs first.  

More Questions?

Contact the Grant and Award Administrator at mwiseman@wnybloodcare.org

The Investigators in the Pathogenesis of Infectious Disease program provides opportunities for assistant professors to bring multidisciplinary approaches to the study of human infectious diseases. It is specifically targeted toward work on the pathogenesis of infectious disease. Work not focused on pathogenesis will not be funded.In general, faculty in their first 2–3 years are not yet competitive for this award.

This award provides $505,000 over a period of five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between infectious agents and their hosts, shedding light on how both are affected by their encounters. Associate professors may not apply. This is a career development award for individual investigators and does not support collaborative teams.

The ideal candidate is an accomplished investigator at the mid-to-late assistant professor level with an established record of independent research in a tenure-track position or its well-supported equivalent in non-tenure offering departments. Very few newly appointed assistant professors are competitive for this award. Most should consider applying later in their career.

Letter of Intent applications due July 17, 2025 by 3:00 pm Eastern Time

Invitation to submit a full proposal October 3, 2025

Full proposal due November 13, 2025 by 3:00 pm Eastern Time

Finalist interviews April 13-15, 2026

Notice of award By May 31, 2026

Award start date July 1, 2026

Award end date June 30, 2031

Applications must be approved and signed by an official responsible for sponsored programs (generally from the grants office, office of research, or office of sponsored

programs) at a degree-granting institution. Candidates will generally have a Ph.D. and/or a clinical doctorate (M.D., D.V.M., etc.).

• Candidates must have an established record of independent research.
• Citizens and non-citizen permanent and temporary residents of the U.S. and Canada who are legally qualified to work in the U.S. or Canada are eligible.
• Candidates who are temporary U.S. residents must hold a valid U.S. visa (J-1, H1B, F-1 or O-1 visas). Temporary
• Canadian residents must hold a valid Canadian visa (Study Permit, C-43, C44, C-10, or C-20 work permits/ visas).
• Candidates who will be promoted to Associate Professor by November 13, 2025 are not eligible to apply.
• Candidates who have completed a Burroughs Wellcome Fund career development award (CAMS or CASI) are encouraged to apply but must contact BWF before writing the LOI. Having had BWF travel, career guidance for trainees, preterm birth, regulatory science, or PDEP grants does not impact PATH support.
• Microbiome-related proposals must be infectious disease-focused to compete well in this program.

Please review our online Frequently Asked Questions first. Questions should be directed in advance to BWF program staff by contacting:

Victoria McGovern, Ph.D., Senior Program Officer, vmcgovern@bwfund.org, 919-991-5112

Darcy Lewandowski, Program Associate, dlewandowski@bwfund.org, 919-991-5132

The AACR Immuno-oncology Research Fellowship represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct immuno-oncology research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or population sciences related and must have direct applicability and relevance to immuno-oncology.



This fellowship provides a two-year grant of $130,000 to support the salary and benefits of the fellow while working on a mentored immuno-oncology research project. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

Applicants must have a doctoral degree (including PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.

At the start of the grant term on November 1, 2025, applicants must:

• Hold a mentored research position with the title of postdoctoral fellow, clinical research fellow, or the equivalent.
• If eligibility is based on a future position, the position must be confirmed at the time of submission and CANNOT be contingent upon receiving this grant.
• If the future position is at a different institution than the applicant’s current institution, the applicant must contact AACR’s Research and Grants Administration Department (AACR’s RGA) at grants@aacr.org before submitting their application for information on additional verification materials/signatures that may be required.
• Have completed their most recent doctoral degree within the past five years (i.e., degree cannot have been conferred before November 1, 2020; the formal date of receipt of doctoral degree is the date the degree was conferred, as indicated on your diploma and/or transcript)
• Applicants with a medical degree must have completed their most recent doctoral degree or medical residency - whichever date is later - within the past five years.
• Work under the auspices of a mentor at an academic, medical, or research institution anywhere in the world.

There are no citizenship or geographic requirements. However, by submitting an application for this grant, an applicant applying from an institution located in a country in which they are not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which they applied. Applicants must be AACR members in good standing (dues paid for the current year).



The AACR requires applicants to submit an online application by 1:00 p.m. U.S. Eastern Time on Tuesday, July 29, 2025, using the ProposalCentral website at https://proposalcentral.com.

Focus grants are targeted, innovative and potentially high impact studies that seek to inform and even transform suicide prevention efforts.

Letter of Intent due August 1, 2025

Full application for invited applicants due December 7, 2025

Funding: Up to $500,000 per year for up to three years.

Project should be innovative, high-risk, potentially high-yield projects that focus on

specific areas of suicide prevention. Project may be focused on the following goals: addressing short-term suicide risk, reducing the national suicide rate by 20%; or “blue-sky research grants” for impactful research that will achieve significant goals (open to all fields of study).

Link: Research Focus grants | AFSP

The McKnight Brain Research Foundation (MBRF) and the American Federation for Aging Research (AFAR) will provide up to two 3-year awards of $750,000 (USD) each to advanced Assistant Professors and recently appointed Associate Professors (MDs and PhDs.) One award will be made to support studies focusing on clinical translational research and another award toward understanding basic biological mechanisms underlying cognitive aging and age-related memory loss.

The application deadline is August 12, 2025.

To be eligible, the applicant must:

• Have completed research training prior to the beginning of this award (October 1, 2025):
• o PhD candidates: no more than 7 years from the completion of formal post-doctoral research training post-PhD,
• o MD or combined degree candidates: no more than 12 years from the date when finished residency.
• Exceptions to the 7 and 12 year limits may be considered for certain life events (e.g. familial, personal commitments or other exceptional circumstances). An exception request can be submitted by emailing an NIH-style biosketch to AFAR at grants@afar.org at least one week prior to the deadline date.
• Be an independent investigator at the rank of Assistant Professor or Associate Professor (promoted to the rank of Associate Professor no earlier than October 1, 2022), who has received R01 funding (or equivalent funding such as an NIH DP5, R35 or NSF Research awards.)
• Be tenure-track faculty or equivalent in an academic or non-profit institution with evidence of long-term institutional support as indicated by commitment of resources including independent laboratory space, start-up research funds and personnel. Candidates not in a tenure-track position are also eligible and should demonstrate similar evidence of long-term institutional support and not be in a time-limited appointment.
• Have a proven track record of research accomplishments in cognitive aging as indicated by their publications in high-impact journals, awards, and other metrics of peer recognition.
• Provide evidence of institutional commitment as described in a form completed by the Dean or CEO and a letter of commitment signed by the Department Chair.
• Be in full time employment at an academic or non-profit research institution in the United States.

The program does not provide support for:

• Senior faculty, i.e., at the rank of Associate Professor or higher who have held this position before October 1, 2022.
• Assistant Professors who have not yet received R01 or equivalent extramural independent funding.
• Investigators who are conducting research at a federal government or for-profit institution.
• See comment above about disease specific research.

Questions about eligibility and suitability of research project can be addressed to grants@afar.org.

Please refer to the application instructions. Incomplete applications cannot be considered. All applications must be submitted via email to afarapplication@afar.org.

The applications will be reviewed by a committee whose recommendations will be presented to MBRF and AFAR for final funding decisions.

Please review this link which includes suggestions for submitting an LOI or application to AFAR. Click here for our Frequently Asked Questions page. If you are using animals in your research, please review Principles of Animal Use for Gerontological Research or this recent webinar recording from the Nathan Shock Centers of Excellence: https://nathanshockcenters.org/june2021webinar-1

MBRF and AFAR will not provide reviewer critiques to any applicants at any review level.

Timeline:

Application deadline: August 12, 2025

Anticipated Award Announcement: September 30, 2025

Award Start Date: October 1, 2025

Due: August 15, 2025

• Amount: $100,000/1 year or $200,000/2 years

• Priority is given to projects focused on studying or correcting the heterozygous effect of non-UBE3A genes in deletion, the potential results of increasing UBE3A after therapies or for some subtypes of AS, projects studying delivery of therapies and potential for improvement, and symptomatic therapies that impact the daily life of people with Angelman syndrome and their families. Proposals that do not address these topics are still welcome and will be given full consideration.

• Link: Angelman RFP

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

The Leukemia & Lymphoma Society (LLS) has released a Request for Proposals (RFP) for its Equity in Access Research Program, which is dedicated to funding health services research.

The LLS is reissuing the RFP Building Evidence for Effective Interventions to Increase Therapeutic Cancer Clinical Trial Accrual: Promoting Access for Patients from Underrepresented Groups. Awards will be a maximum of $2.5 million each over 5 years.

Specifically, the LLS seeks proposals that will implement and evaluate interventions designed to:

·        Mitigate multilevel barriers to therapeutic clinical trial accrual for underrepresented groups

·        Quantitatively measure the impact of these interventions on patient accrual

The LLS is particularly interested in proposals that address systemic, institutional, and/or clinician-related barriers that impede clinical trial participation.

It is not necessary for applicants to have previously conducted research in blood cancer. The due date for Letters of Intent is September 11, 2025, at 3 pm ET. 



The RFP and additional information are available at LLS.org/EquityinAccess.

The Leukemia & Lymphoma Society’s Career Development Program (CDP) supports scientists studying basic, translational, or clinical research to help understand and treat hematologic malignancies and relevant premalignant conditions.

The program welcomes applications worldwide from appropriate non-profit academic institutions and investigators of any nationality. Non-citizens and non-residents are eligible. You do not need a green card to apply or hold the CDP award.

Application Deadlines

Eligibility Phase Deadline October 17, 2025; 3:00 PM (ET)

Letter of Intent Phase Deadline November 1, 2025, 3:00 PM (ET)

Blind Letters of Reference Deadline:November 15, 2025, 3:00 PM (ET)

Full Application Phase Deadline November 15, 2025, 3:00 PM (ET)

Award Start Date July 1, 2026

Research Subject Matter 

CDP applicants must have a research focus on hematological malignancies and relevant premalignant conditions. We are interested in all research studies on any of these subjects. The research may have a basic mechanistic focus to better understand these diseases or may be preclinical/clinical studies using any approach with the goal of achieving better therapeutic outcomes. 

Award Categories:

Scholar. These 5-year, $120,000/year awards support emerging leaders in the blood cancer research field. You must be a highly qualified, early/mid-career laboratory-based investigator who has an impactful and innovative research program focused on hematologic malignancies and/or relevant premalignant conditions. You must hold an independent, tenure-track, faculty-level position and should have substantial research support from a national agency.

Scholar in Clinical Research. These 5-year, $125,000/year awards support highly qualified clinical investigators who hold an independent faculty-level appointment and are conducting independent applied research that will advance the prevention, diagnosis, and/or treatment of hematologic malignancies and/or relevant premalignant conditions. The research must involve patients and be related to your overall clinical activities. You must have substantial support for your research from another source.

Special Fellow. These 2 or 3 year, $75,000/year awards support highly qualified, mentored postdoctoral fellows and instructors who have 3-5 years of postdoctoral research training (as of the award start date) and are continuing a research program of direct relevance to hematological malignancies and/or relevant premalignant conditions. In addition, your Sponsor must have the appropriate experience to mentor you as you engage in blood cancer research. This award provides you with the opportunity to continue building a research program that will make you competitive for an independent position by the end of the award funding period.

Fellow. These 3-year, $70,000/year awards support top performing, mentored postdoctoral fellows and instructors who are training for a career in hematological malignancy research and/or treatment and who have up to 3 years of postdoctoral research training (as of the award start date). Your Sponsor must have the appropriate experience to mentor you as you engage in blood cancer research.

Application Process:

The application process has three phases. The first phase is submission and consideration of eligibility. All eligible applicants will be invited to proceed to the Letter of Intent and Full Application phases. All submissions must be made through the LLS Research Portal.

Please visit our website, https://www.lls.org/research/apply-career-development-program-cdp for how to apply. Detailed instructions for each award category are found in the CDP Guidelines and Instructions.

For questions, please contact researchprograms@lls.org.

The College of Medicine would like to submit one candidate’s application for consideration for the 2026 Searle Scholars Program from the Kinship Foundation. The Searle Scholars Program Scientific Advisory Board is primarily interested in the potential of applicants to make innovative and high-impact contributions to research over an extended period of time. 

Grants are set at $300,000 for a three-year period with $100,000 payable in the first year and equal sums payable in the second and third years and are subject to the receipt of acceptable progress reports. Generally, fifteen new awards are granted annually. Awards will be activated on July 1, 2026. 

Eligibility of the applicant: 

• Applicants should have begun their appointment as an independent investigator at the Assistant Professor level on or after May 1, 2024. The appointment must be their first tenure-track position. 
• Applicants are expected to be pursuing independent research careers in biochemistry, cell biology, genetics, immunology, neuroscience, pharmacology, and related areas in chemistry, medicine, and the biological sciences. 
• The Searle Scholars Program does not ordinarily support purely clinical research but has supported research programs that include both clinical and basic components. Potential applicants who are unsure if their research is appropriate for the Program are encouraged to examine the research interests of present and former Searle Scholars on this website. The 2025 Searle Scholars are listed here.

In order to implement the application process for this competition, eligible faculty members are invited to submit preliminary applications, upon the recommendation of the appropriate department chair(s), for review by the Awards Committee. From among these applications, the Committee will make recommendations and will select one candidate, who will be invited to submit the full proposal to the Kinship Foundation by 5:00 pm, September 30, 2024. 

The deadline for submission of preliminary applications for internal review by the Awards Committee is Friday 5 pm, August 22^nd, 2025. 

Non-tenured track Assistant Professors, Research Assistant Professors, and Staff Scientists are not eligible for internal nomination.

For internal review of your application by the Awards Committee, please send a single (ONE) PDF file containing the following as an email attachment to applicationsubmission@einsteinmed.edu: 

1. Candidate Profile Form (attached).
2. A statement outlining the applicant’s career potential and the Department’s plans for his/her future to be obtained from the Department Chairperson, limited to no more than TWO single-spaced pages. 
3. A written proposal containing a title and a description of the proposed research project to be carried out during the grant period, limited to no more than three single-spaced pages, plus one additional page (single spaced) for references with titles included. The font must be 11 point or larger, and the margins should be at least 0.5 inches. Figure legends can use smaller fonts. 
4. A complete curriculum vitae and bibliography. Include invited presentations but not abstracts. Please click here to find the recommended format for curriculum vitae.
5. Information about present and pending grant support with amounts requested or approved, annual amounts, and duration of award. 

To know in advance about the award and reporting requirements by the Kinship Foundation, please visit the Searle Scholars Program Award Information Page. The Searle Scholars Program accepts nominated applications only through their online application system. Once our Awards Committee selects the nominee, we will assist the nominated candidate to submit the final application to the Kinship Foundation. 

If you have any questions concerning this award or the application procedure, please contact applicationsubmission@einsteinmed.edu.